Teprotumumab Bests Placebo for Active Thyroid Eye Disease

THURSDAY, Jan. 23, 2020 -- Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published in the Jan. 23 issue of the New England Journal of Medicine. Raymond S. Douglas,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news